Based on the aggregated intelligence of 120,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech company Exelixis (NASDAQ:EXEL) has earned a coveted five-star ranking. Our data has shown that five-star stocks outperform the market by a significant margin; conversely, one-star stocks have woefully lagged the market average.

With that in mind, let's take a closer look at Exelixis' business, and see what CAPS investors are saying about the stock right now.

Exelixis facts  

Headquarters (founded)

San Francisco, California (1994)

Market Cap

$253.44 million

Industry

Biotechnology

TTM Revenue

$117.54 million

Management

Co-Founder/Chairman Dr. Stelios Papadopoulos

CEO Dr. George Scangos

Compound Annual Revenue Growth (over last five years)

18.5%

Competitors

Novartis (NYSE:NVS),

Genentech (NYSE:DNA)

CAPS members bullish on EXEL also bullish on

General Electric (NYSE:GE),

Apple (NASDAQ:AAPL)

CAPS members bearish on EXEL also bearish on

Wachovia (NYSE:WB),

General Motors (NYSE:GM)

Sources: Capital IQ, a division of Standard & Poor's, and Motley Fool CAPS. TTM = trailing 12 months.

Over on CAPS, fully 2,177 of the 2,255 members who have rated Exelixis -- more than 96% -- believe the stock will outperform the S&P 500 going forward. These Foolish bulls include wolfhounds and zzlangerhans.

Last month, wolfhounds wrote that Exelixis "distinguishes itself by the number of compounds in development, the large pharma partners ponying up cash, and the science they have proven with the latest stage compounds. Patience should pay off with this stock."

In a pitch two weeks later, zzlangerhans agrees, highlighting the stock's cheapish valuation (which is even better today) as reason to jump in:

Ah, Exelixis. You've broken so many hearts over the years. With your everwidening and never-lengthening pipeline, sometimes you seem like you're already the biotech subdivision of a large pharmaceutical company. Is that what your dream is? Now that your cap is below 400M you may finally achieve it. I finally see a price I like.

What do you think about Exelixis, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 120,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Exelixis is a Motley Fool Rule Breakers recommendation. Apple is a Stock Advisor pick. The Fool owns shares of Exelixis. The Fool's disclosure policy always gets a perfect score.